A new spinout from the University of Otago has secured $14 million in backing to help develop a new kind of targeted cancer drug in the emerging field of RNA therapy.
The Amaroq Therapeutics team, led by chief scientific officer and founder Dr Sarah Diermeier, are pioneers in exploring the use
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
